Kuban Deborah A, Thames Howard D, Levy Larry B
Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 97, TX 77030, Houston, USA.
World J Urol. 2003 Sep;21(4):253-64. doi: 10.1007/s00345-003-0361-0. Epub 2003 Aug 16.
The introduction of prostate-specific antigen (PSA) as a reliable tumor marker for prostate cancer brought significant changes in endpoints after therapy and in outcome reporting. Over the last 15 years we have collected follow-up information in this new era and struggled with failure definitions using this new tool. Parameters for failure after radiation were especially controversial due to the fact that, unlike surgery, a variable amount of normal prostate function and PSA production remained. In 1996, the ASTRO Consensus Conference established a PSA failure definition based on the available information at the time. It was commonly used for outcome reporting subsequently although criticisms have been voiced and alternate definitions proposed. A recently assembled multi-institutional database was used both for long-term outcome reporting with external beam radiation and to test various other failure definitions. A summary of these results and the associated issues are presented here.
前列腺特异性抗原（PSA）作为前列腺癌可靠的肿瘤标志物的引入，给治疗后的终点指标以及结果报告带来了重大变化。在过去15年里，我们收集了这个新时代的随访信息，并在使用这一新工具时为失败定义而纠结。放疗后失败的参数尤其具有争议性，因为与手术不同，仍保留了不同程度的正常前列腺功能和PSA产生。1996年，美国放射肿瘤学会（ASTRO）共识会议根据当时可用的信息确立了PSA失败定义。尽管有人提出批评并给出了替代定义，但该定义随后普遍用于结果报告。最近组建的一个多机构数据库既用于外照射放疗的长期结果报告，也用于测试各种其他失败定义。本文介绍了这些结果及相关问题的总结。
